Insider · CIK 0001822092
Christy J. Oliger
director
Files at KPTI (Karyopharm Therapeutics Inc.), REPL (Replimune Group, Inc.), VERA (Vera Therapeutics, Inc.), LVTX (LAVA Therapeutics NV), NUVL (Nuvalent, Inc.), ZBIO (Zenas BioPharma, Inc.). First filing -, latest -.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 0
$0 bought, $0 sold
Signals
This insider’s open-market buys and sells, scored.
No scored open-market trades yet.
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | ZBIO Zenas BioPharma, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +37,000 | $0.00 | $0 | 37,000 | 40 d ago |
| Jun 18, 2025 | NUVL Nuvalent, Inc. | AGrant or award Class A Common Stock | +3,971 | $0.00 | $0 | 3,971 | Jun 20, 2025 |
| Jun 18, 2025 | NUVL Nuvalent, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +6,119 | $0.00 | $0 | 6,119 | Jun 20, 2025 |
| May 28, 2025 | KPTI Karyopharm Therapeutics Inc. | AGrant or award Nonstatutory Stock Option (right to buy)derivative | +4,600 | $0.00 | $0 | 4,600 | May 29, 2025 |
| May 14, 2025 | VERA Vera Therapeutics, Inc. | AGrant or award Stock Option (right to buy)derivative | +14,000 | $0.00 | $0 | 14,000 | May 16, 2025 |
| Apr 1, 2025 | REPL Replimune Group, Inc. | AGrant or award Stock Option (right to buy)derivative | +32,000 | $0.00 | $0 | 32,000 | Apr 3, 2025 |
| Feb 13, 2025 | LVTX LAVA Therapeutics NV | AGrant or award Common Shares (Right to Buy)derivative | +33,390 | $0.00 | $0 | 33,390 | Feb 18, 2025 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.